We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.87B
1-Year Est. Return 205.24%
This Fund
S&P 500
This Quarter Est. Return
+39.07%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.38B
AUM Growth
+$198M
Cap. Flow
-$28.4M
Cap. Flow %
-1.19%
Top 10 Hldgs %
45.26%
Holding
80
New
15
Increased
16
Reduced
23
Closed
20

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$84.7M
2
INSM icon
Insmed
INSM
+$82.4M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$61.2M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$50.7M
5
AUTL
Autolus Therapeutics
AUTL
+$37.9M

Top Sells

Rank Stock Value
1
NVCR icon
NovoCure
NVCR
+$98.3M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$80M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$51.5M
4
KURA icon
Kura Oncology
KURA
+$43.5M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 96.31%
2 Miscellaneous 3.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
76
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-2,000,000
Closed -$35.9M
TCDA
77
CALL
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-772,700
Closed -$8.1M
TCDA
78
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-1,177,680
Closed -$12.3M
FMTX
79
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
– –
-966,573
Closed -$19.3M
GBT
80
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-326,600
Closed -$22.2M
1 2 3
4

Similar funds

PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
NP
NorthRock Partners Minneapolis, Minnesota $6.89B AUM 19.83% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return
RCWMU
Rothschild & Co Wealth Management (UK) London, United Kingdom $6.93B AUM 1.4% 1-Year Est. Return
CA
Cambridge Associates Boston, Massachusetts $6.93B AUM 17.96% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return
CI
Cincinnati Insurance Fairfield, Ohio $6.94B AUM 20.24% 1-Year Est. Return

Deep Track Capital's Q4 2022 Portfolio in Review

As of Q4 2022, Deep Track Capital held 80 positions worth $2.38B, up 9.1% from $2.18B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Deep Track Capital's Q4 2022 filing shows 15 new, 16 increased, 23 reduced and 20 closed positions. Its largest new stake was Biogen: 300,000 shares worth $83.1M. The largest sale was NovoCure, an estimated $98.3M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 93% a quarter earlier, followed by Miscellaneous.

  • Deep Track Capital's largest Q4 2022 buy was Biogen: 300,000 shares worth $83.1M.
  • Deep Track Capital added most to DICE Therapeutics, Inc. Common Stock in Q4 2022, an estimated $23.9M increase.
  • Deep Track Capital's biggest Q4 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $80M.
  • Deep Track Capital fully exited NovoCure in Q4 2022, selling an estimated $98.3M.
  • Deep Track Capital's ten largest holdings make up 45% of its $2.38B portfolio in Q4 2022.
  • Deep Track Capital opened 15 new positions and closed 20 in Q4 2022.
  • Deep Track Capital's portfolio value rose 9.1% quarter-over-quarter to $2.38B.

Based on Deep Track Capital's 13F filing for Q4 2022, filed 14 Feb 2023.